Skip to content
Research Article Open access CC BY 4.0

Formulation and Characterisation of RGD-FBG Based Nanoscaffolds as Novel Anti-Cancer Drug Delivery System

Deepa Patel, Drashti Pathak

Journal of Pharmaceutical Research International · pp. 9–17 · Published 9 Feb 2022

10.9734/jpri/2022/v34i8B35479

Abstract

Aims/Objective: To formulate and evaluate RGD sequenced fibrin/fibrinogen based nanoscaffolds (acid-labile linker) for the treatment of brain tumor targeting to achieve an acid-triggered drug release under a mild acidic condition in tumor. Place and Duration of Study: Department of Pharmaceutics, Parul Institute of Pharmacy and Research, Parul University, Vadodara, between 2017 to 2021. Methodology: Nanoscaffolds was prepared with Drug–linker–Fbg conjugate solution, using modified water-in-oil (W/O) emulsification/solvent extraction method. The conjugate solution was constantly injected in soya lecithin (100 ml) using a syringe (1 ml/min) and stirred using Magnetic stirrer for 30 minutes to form stable a W/O emulsion. The present investigation was aimed to evaluate with Particle size, Zeta potential measurement, Percent drug entrapment, Transmission electron microscopy. Results:  As per Evaluation parameters were performed such as Particle size measured as 151.8±2.02 nm to 157.4 ± 3.81 nm. Zeta Potential was found that -37.1±6.32, Percent Drug Entrapment was 91.4±0.37 which indicates that the drug release of lyophilised FBG based nanoscaffolds was indicatively higher as compared to FBG based nanoscaffolds (alone). Conclusion: As per the study design the formulated nanoscaffolds were found to impart the drug release based on their particle size and percent drug entrapment and hence fights against cancer cells in brain by their EDC-NHS chemistry. Drug of choice Everolimus along with Fbg based nanoscaffolds offers better biocompatibility by exposing dual responsiveness at acidic environment in tumors. The results of in-vitro drug release reveals the better uptake of drug at targeted site of action.

Everolimus nanoscaffols In-vitro drug release

References (18)

  1. 1 Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease [DOI]
  2. 2 Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder [DOI]
  3. 3 Design of Experiments (DoE) applied to Pharmaceutical and Analytical Quality by Design (QbD) [DOI]
  4. 4 Basic & clinical pharmacology & toxicology
  5. 5 Effects of physicochemical properties and other factors on systemic nasal drug delivery [DOI]
  6. 6 Monoaminergic system and depression [DOI]
  7. 7 Cyclodextrin‐Based Formulations: A Non‐Invasive Platform for Targeted Drug Delivery [DOI]
  8. 8 Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa [DOI]
  9. 9 Factors influencing drug deposition in the nasal cavity upon delivery via nasal sprays [DOI]
  10. 10 Formulation and device design to increase nose to brain drug delivery [DOI]
  11. 11 How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods [DOI]
  12. 12 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects [DOI]
  13. 13 Development and Evaluation of a Novel Intranasal Spray for the Delivery of Amantadine [DOI]
  14. 14 Assessment of the influence factors on in vitro testing of nasal sprays using Box-Behnken experimental design [DOI]
  15. 15 A quantitative LC-MS/MS method for simultaneous determination of deuvortioxetine, vortioxetine and their carboxylic acid metabolite in rat plasma, and its application to a toxicokinetic study [DOI]
  16. 16 Quality by design (QbD) approach for design and development of drug-device combination products: a case study on flunisolide nasal spray [DOI]
  17. 17 The Black Book of Psychotropic Dosing and Monitoring
  18. 18 Journal of Pharmaceutical Investigation [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.